Nidec Announces its Win of Damages Case against Toyo Keizai Inc.
Nidec Announces its Win of Damages Case against Toyo Keizai Inc.
Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) (“Nidec” or the “Company”) today announced that it has received a ruling in favor of the Company in the action that it instituted against Toyo Keizai Inc. (head office: 1-2-1 Nihonbashi, Hongokucho, Chuo-ku, Tokyo) and concerned individuals to the Tokyo District Court on October 24, 2022, demanding damages based on the defamation by the aforementioned parties.
In its ruling, the Tokyo District Court, citing, among other reasons, that Toyo Keizai Inc.’s reporting on the Company’s alleged act of insider trading is false, and that the coverage of the reporting was insufficient, found the reporting by Toyo Keizai Inc. did defame Nidec’s reputation, and ordered Toyo Keizai Inc. and concerned individuals to pay damages to the Company, and to remove the article in question.
This ruling makes it clear that Nidec properly acquired treasury stock in accordance with applicable laws and regulations, and that the Company is free of suspicions over insider trading.
Nidec stays committed to conducting business activities in accordance with applicable laws and regulations.
Teruaki Urago
General Manager
Investor Relations
+81-75-935-6140
ir@nidec.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806134999/en/
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks